Despite being the core debate question, causality remains unresolved due to reliance on cross-sectional human data and artificial animal models. The expert noted this chicken-and-egg problem prevents optimal therapeutic targeting strategies.
Source: Debate session sess_SDA-2026-04-16-gap-pubmed-20260411-082446-2c1c9e2d (Analysis: SDA-2026-04-16-gap-pubmed-20260411-082446-2c1c9e2d)
Soluble amyloid oligomers may injure cholinergic terminals via CHRNA7-linked calcium dysregulation, making cholinergic dysfunction an early downstream readout of amyloid toxicity. This remains mechanistically plausible but is not a strong lead translational thesis.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["Amyloid Accumulation"]
B["Alpha7 Nicotinic Receptor Dysfunction"]
C["CHRNA7 Synaptotoxicity"]
D["Cholinergic Terminal Loss"]
E["Cognitive Impairment"]
A --> B
B --> C
C --> D
D --> E
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style E fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Median TPM across 13 brain regions for APP, CHRNA7 from GTEx v10.
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
Aβ-CHRNA7 binding and functional relevance are inconsistent across preparations and model systems, with weak h…▼
Aβ-CHRNA7 binding and functional relevance are inconsistent across preparations and model systems, with weak human specificity for cholinergic terminals.
Alpha7-targeted cognition programs have had a poor clinical track record, limiting confidence in translational…▼
Alpha7-targeted cognition programs have had a poor clinical track record, limiting confidence in translational value.
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-25 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Basal forebrain NGF/TrkA failure is an upstream trigger that makes cholinergic neurons permissive to later amyloid and tau spread
Mechanism: Early loss of retrograde NGF signaling from cortex/hippocampus to nucleus basalis cholinergic neurons reduces `NTRK1 (TrkA)` survival signaling, impairs axonal transport, and lowers cortical acetylcholine release. This produces synaptic inactivity, endosomal stress, and impaired APP trafficking, which then biases vulnerable projection fields toward increased amyloidogenic processing and later tau propagation.
*Target gene/protein/pathway:
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
NGF/TrkA failure is upstream
Weak evidence: Most human support is correlational and late-stage. Reduced `NTRK1`/NGF signaling could be a consequence of early tau, endosomal stress, or synapse loss rather than the initiating lesion. “Before severe neuron loss” does not establish before soluble Aβ or seed-competent tau. Alternative mechanisms: Early tau in entorhinal-limbic circuits, APP/endosomal defects, mitochondrial failure, or vascular hypoperfusion could independently cause both cholinergic dysfunction and apparent NGF signaling failure. Translational risks: iPSC cholinergic neurons
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Bottom Line
The ideas worth carrying forward are `#5 endosomal-trafficking-first`, `#7 subtype-specific ordering`, `#1 NGF/TrkA trophic failure`, and `#3 APOE4-complement pruning`. `#4 locus coeruleus gating` is useful mainly as a stratification axis, not as a primary drug program. I would drop `#2 alpha7-nAChR amyloid synaptotoxicity` and `#6 astrocytic cholinesterase niche` as lead translational bets.
Priority Order
`#5 Endosomal trafficking defects are the common upstream lesion`
Druggability is moderate now and potentially high later: `SORL1/retromer` is genetically anchored,
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{"ranked_hypotheses":[{"title":"Endosomal trafficking defects are the common upstream lesion linking APP processing and cholinergic degeneration","description":"AD-risk trafficking defects in SORL1/BIN1/PICALM/retromer may generate parallel early outputs: amyloidogenic APP sorting and selective basal-forebrain cholinergic trophic failure. This best fits the debate because it explains why temporal order can appear inconsistent across cohorts without requiring a single linear sequence.","target_gene":"SORL1, BIN1, PICALM, VPS35, APP, NTRK1","dimension_scores":{"evidence_strength":0.82,"novelty":
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
💬 Discussion
Loading comments...
No DepMap CRISPR Chronos data found for APP, CHRNA7.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
IF human iPSC-derived cholinergic neurons are exposed to soluble amyloid-β oligomers (500 nM, 24-72 hours) THEN cholinergic terminal integrity (measured by VAChT puncta density and ChAT activity) will decrease by ≥40% compared to vehicle-treated controls, and this effect will be fully blocked by co-treatment with CHRNA7 antagonist (alpha-bungarotoxin 100 nM or PNU-120596 1 μM).
pendingconf: 0.55
Expected outcome: Significant reduction in cholinergic terminal markers (VAChT puncta: 40-60% decrease; ChAT activity: 30-50% decrease) that is rescued by CHRNA7 blockade
Falsified by: CHRNA7 antagonist fails to provide statistically significant protection (>20% rescue) against Aβ-induced cholinergic terminal loss; or Aβ oligomers fail to impair cholinergic terminals at all
Method: In vitro experiment using human iPSC-derived cholinergic neurons (or iPSC-derived basal forebrain cholinergic neurons from multiple donors, n≥3 lines) treated with AβO (Aβ1-42 oligomers), with CHRNA7 pharmacological blockade, measuring VAChT immunofluorescence, ChAT activity assay, and cell viability controls
IF APP/PS1 transgenic mice are treated with a selective CHRNA7 positive allosteric modulator (PAM) starting at 3 months of age (pre-plaque) and continuing for 6 months THEN cholinergic terminal density in hippocampus (measured by VAChT immunoreactivity and [3H]NC-HEK binding) will be preserved at levels comparable to wild-type mice, while vehicle-treated APP/PS1 mice will show ≥30% cholinergic terminal loss.
pendingconf: 0.45
Expected outcome: Cholinergic terminal preservation in CHRNA7 PAM-treated APP/PS1 mice; VAChT density maintained at 85-100% of wild-type levels vs. 60-70% in vehicle-treated APP/PS1
Falsified by: CHRNA7 PAM treatment fails to preserve cholinergic terminals (no significant difference between treated APP/PS1 and vehicle-treated APP/PS1); or amyloid deposition occurs normally despite terminal preservation
Method: In vivo experiment using APP/PS1ΔE9 mice (or 5xFAD mice) treated with CHRNA7 PAM (e.g., TQS, BMS-935177, or JNJ-39310234 at 10-30 mg/kg/day via drinking water) from 3-9 months of age, with longitudinal PET imaging for amyloid (11C-PiB or 18F-AV45) and post-mortem stereological quantification of cholinergic terminals in hippocampus and basal forebrain